このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Impact of Nutritional Managment on Pregnancy With IBD Patients and Their Springs (IBD/pregnancy)

2026年5月5日 更新者:Amira Mohammed Abdel Mowgod、Assiut University
While diet can support IBD management, with the potential to positively benefit perinatal as well as longer-term health outcomes, little is known about the quality of dietary patterns among pregnant women with IBD , therefore, the objectives of our study are to assess the dietary patterns and diet quality of pregnant women with IBD, and to examine the associations between dietary patterns, diet quality, and dietary guidelines for pregnancy and growth of their offerings

調査の概要

状態

まだ募集していません

詳細な説明

Pregnancy is a critical time for the intergenerational transmission of health (. Pregnant women with active inflammatory bowel disease (IBD), a chronic disease characterized by inflammation of the gastrointestinal tract are considered to be at higher risk of poor pregnancy outcomes such as preterm birth, low birthweight or small for gestational age (SGA), spontaneous abortion, and stillbirth, and comprise an increased percentage of Cesarean deliveries compared to women in remission or without IBD. The prevalence of IBD has been increasing worldwide; thus, improving the health of pregnant women with IBD is essential to decreasing their risk for adverse pregnancy outcomes.

A balanced perinatal diet can support optimal health for pregnant women and have a long-term impact on their offspring. Patients with IBD are already prone to nutrition deficiencies due to factors such as restrictive diets, nutrient loss, drug-nutrient interaction, and decreased absorption from the ileum. Furthermore, reduced oral intake and chronic inflammation increases nutrient needs among IBD patients. Two reports have explored the diets of pregnant women in the Norwegian Mother and Child Cohort (MoBa). The first study found that compared to pregnant women without IBD, pregnant women with IBD were less likely to adhere to a traditional Norwegian dietary pattern characterized by a high intake of lean fish or fish products, potatoes, rice porridge, cooked vegetables, and gravy, and were more likely to adhere to a Western dietary pattern with higher intake of foods and beverages rich in sugar and saturated fats. Moreover, pregnant women with IBD who did adhere to the traditional Norwegian diet had lower odds of having an SGA infant. The second study found that pregnant women with IBD consumed a lower proportion of protein from dairy products compared to pregnant women without IBD. In this case, a reduced intake of protein from dairy was associated with a lower risk of having an SGA infant.

Maternal diet during pregnancy has also been linked to the infant microbiome composition, which is critical for the priming of a balanced immune system during early life. Importantly, it was demonstrated that infants born to women with IBD have less diverse microbiomes and higher levels of fecal calprotectin (a biomarker of intestinal inflammation) compared to the infants of women without IBD. Along with emerging reports demonstrating the mediating role of the gut microbiota in the effectiveness of dietary interventions for IBD management, this finding suggests that improving dietary patterns during pregnancy may beneficially modify the microbiome composition, thereby promoting both maternal and infant health. This hypothesis is being explored by the MELODY (Modulating Early Life Microbiome through Dietary Intervention in Pregnancy) Trial Diet has been increasingly integrated into IBD management, and studies demonstrate the effectiveness of dietary interventions for inducing IBD remission. In adults, the specific carbohydrate diet (SCD); the Mediterranean diet; the low fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (low FODMAP) diet; and the anti-inflammatory IBD (IBD-AID) diet are among those that have shown efficacy in reducing disease activity and symptoms. Yet, informational resources on nutrition for pregnant women with IBD are sparse. The USDA MyPlate website focuses on a variety of food groups with only broad suggestions of foods and meal plans specific to pregnancy and postpartum needs. The 2014 and 2017 American College of Obstetricians and Gynecologists (ACOG) guideline statements seem focused on nutrients that may be obtained by taking a prenatal vitamin, rather than on whole foods. The 2019 American Gastroenterological Association's Inflammatory Bowel Disease in Pregnancy Clinical Care Pathway report encourages nutrition consultation for specific nutrient deficiency and weight gain patterns in this population, but with few details on compliance to guidelines. In keeping with these publications, pregnant women may hear only general advice from health care providers to take a prenatal vitamin, follow a healthy diet, limit caffeine intake, avoid alcohol and tobacco, and observe caution with seafood. However, while a prenatal vitamin may be recommended in addition to a healthy diet, it cannot supply all the nutrients that are needed to promote healthy and low-risk pregnancies.

研究の種類

観察的

入学 (推定)

50

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人

健康ボランティアの受け入れ

いいえ

サンプリング方法

確率サンプル

調査対象母集団

  • Patients underwent clinical, laboratory, endoscopic, and/or imaging evaluations as part of routine outpatient monitoring.
  • Laboratory investigations (Complete blood picture, Liver function tests, C-reactive protein and ESR, Fecal calprotectin).
  • The following variables were evaluated: age, sex, BMI [weight (kg)/height (m)²], Calories per day, vitamins intake, method of divert, offsprings evaluation ( weight, height, head circumference, growth velocity, lactation evaluation and vitamins intake), history of IBD-related surgeries, current and prior concomitant medications, disease duration

説明

Inclusion Criteria:

  • All pregnant women and documented IBD diagnosis.
  • The diagnosis of IBD was based on the patient's history supported by clinical, endoscopic and histologic documentation

Exclusion Criteria:

  • Inability to provide informed consent
  • HIV/Aids, multi-fetus pregnancy, fetal chromosomal or structural abnormalities
  • intrauterine growth restriction, active infection (including chorioamnionitis or sepsis), renal disease, or a dietary regime that conflicts with the intervention diet.
  • Pregnant IBD patients who had active perianal or extra-intestinal disease or were treated with antibiotic therapy or steroids at recruitment
  • Women scheduled for C-section prior to week 37

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Dietary Patterns and Diet Quality Among Pregnant Women with Inflammatory Bowel Disease and Their Association with Pregnancy Outcomes and Infant Growth
時間枠:Data collection: During pregnancy (across trimesters) and follow-up until infant growth assessment (e.g., up to 12-24 months after delivery)
This study aims to evaluate dietary patterns and overall diet quality among pregnant women diagnosed with Inflammatory Bowel Disease. It further seeks to examine the relationship between maternal dietary patterns, adherence to pregnancy dietary guidelines, and their impact on perinatal outcomes as well as infant growth. The findings are expected to provide insights into nutritional gaps and inform dietary recommendations for this specific population.
Data collection: During pregnancy (across trimesters) and follow-up until infant growth assessment (e.g., up to 12-24 months after delivery)

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年7月1日

一次修了 (推定)

2027年4月1日

研究の完了 (推定)

2028年4月1日

試験登録日

最初に提出

2026年4月24日

QC基準を満たした最初の提出物

2026年4月24日

最初の投稿 (実際)

2026年5月1日

学習記録の更新

投稿された最後の更新 (実際)

2026年5月11日

QC基準を満たした最後の更新が送信されました

2026年5月5日

最終確認日

2026年4月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • 04-2026-300837

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する